1-9 of 9
Boris Freidlin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN)

Yixuan Zhao, Ying Yuan, Edward L. Korn, Boris Freidlin
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 673–679.
https://doi.org/10.1158/1078-0432.CCR-23-2585
Published: 16 February 2024
View article titled, Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN)
Open the PDF for Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN) in another window
Includes: Supplementary data
Journal Articles

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Funda Meric-Bernstam, James M. Ford, Peter J. O'Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin, Roisin E. O'Cearbhaill, Suzanne George, Julia Glade-Bender, Gary H. Lyman, James V. Tricoli, David Patton, Stanley R. Hamilton, Robert J. Gray, Douglas S. Hawkins, Bhanumati Ramineni, Keith T. Flaherty, Petros Grivas, Timothy A. Yap, Jordan Berlin, James H. Doroshow, Lyndsay N. Harris, Jeffrey A. Moscow
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1412–1422.
https://doi.org/10.1158/1078-0432.CCR-22-3334
Published: 14 April 2023
View article titled, National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Open the PDF for National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) in another window
Includes: Supplementary data
Journal Articles

Abstract PO-092: Expanded access trial of tocilizumab in COVID19+ hospitalized cancer patients

Nirali N. Shah, Percy Ivy, Rebecca Enos, Matthew J. Boron, Rodney Howells, Boris Freidlin, Carmen Allegra, Margaret M. Mooney, Worta McCaskill-Stevens, James H. Doroshow, Richard F. Little
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18_Supplement): PO-092.
https://doi.org/10.1158/1557-3265.COVID-19-PO-092
Published: 15 September 2020
View article titled, Abstract PO-092: Expanded access trial of tocilizumab in COVID19+ hospitalized cancer patients
Journal Articles

Surrogate and Intermediate Endpoints in Randomized Trials: What's the Goal?

Edward L. Korn, Boris Freidlin
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (10): 2239–2240.
https://doi.org/10.1158/1078-0432.CCR-18-0183
Published: 14 May 2018
View article titled, Surrogate and Intermediate Endpoints in Randomized Trials: What's the Goal?
Open the PDF for Surrogate and Intermediate Endpoints in Randomized Trials: What's the Goal? in another window
Journal Articles

Borrowing Information across Subgroups in Phase II Trials: Is It Useful?

Boris Freidlin, Edward L. Korn
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (6): 1326–1334.
https://doi.org/10.1158/1078-0432.CCR-12-1223
Published: 14 March 2013
View article titled, Borrowing Information across Subgroups in Phase II Trials: Is It Useful?
Open the PDF for Borrowing Information across Subgroups in Phase II Trials: Is It Useful? in another window
Journal Articles

The Cross-Validated Adaptive Signature Design

Boris Freidlin, Wenyu Jiang, Richard Simon
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (2): 691–698.
https://doi.org/10.1158/1078-0432.CCR-09-1357
Published: 14 January 2010
View article titled, The Cross-Validated Adaptive Signature Design
Open the PDF for The Cross-Validated Adaptive Signature Design in another window
Journal Articles

Multi-Arm Clinical Trials of New Agents: Some Design Considerations

Boris Freidlin, Edward L. Korn, Robert Gray, Alison Martin
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (14): 4368–4371.
https://doi.org/10.1158/1078-0432.CCR-08-0325
Published: 15 July 2008
View article titled, Multi-Arm Clinical Trials of New Agents: Some Design Considerations
Open the PDF for Multi-Arm Clinical Trials of New Agents: Some Design Considerations in another window
Journal Articles

Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients

Boris Freidlin, Richard Simon
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7872–7878.
https://doi.org/10.1158/1078-0432.CCR-05-0605
Published: 08 November 2005
View article titled, Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients
Open the PDF for Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients in another window
Journal Articles

A Model to Select Regimens for Phase III Trials for Patients with Advanced-Stage Non-Small Cell Lung Cancer

Boris Freidlin, Oscar S. Breathnach, Bruce E. Johnson
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (3): 917–922.
Published: 01 March 2003
View article titled, A Model to Select Regimens for Phase III Trials for Patients with Advanced-Stage Non-Small Cell Lung Cancer
Open the PDF for A Model to Select Regimens for Phase III Trials for Patients with Advanced-Stage Non-Small Cell Lung Cancer in another window